Figure 8
Therapeutic efficacy of HexAbs in disseminated JeKo-1 xenograft model. Seven groups of 8 mice (8-week-old female SCID mice) each were inoculated intravenously with JeKo-1 (2.5 × 107 cells per animal). After 7 days, 3 different does (ie, 370, 37, and 3.7 μg) of both HexAbs were administered by intraperitoneal injections twice a week for 2 weeks. Control mice received saline injections. 74-(20)-(20) and 20-(74)-(74), at the 370-μg dose level, resulted in 30% and 60% increases in median survival compared with saline controls, respectively.
